<DOC>
	<DOCNO>NCT00276926</DOCNO>
	<brief_summary>The purpose study assess clinical anti-proliferative activity STI571 ( Glivec® , Novartis , Pharma ) patient HES define : 1 . Idiopathic Hypereosinophilic Syndrome ( secondary HES ) , define peripheral blood eosinophilia great 1,500 cells/µL longer 6 month , absence apparent aetiology eosinophilia without sign symptom organ involvement , irrespective expression imatinib target ( c-Kit receptor , PDGFR , bcr-abl receptor ) bone marrow cell . 2 . Familiar hypereosinophilia define peripheral blood eosinophilia great 1,500 cells/µL longer 6 month , absence apparent aetiology eosinophilia sign symptom organ involvement , irrespective expression imatinib target ( c-Kit receptor , PDGFR , bcr-abl receptor ) bone marrow cell , recognize report case hypereosinophilia patient 's family . 3 . Chronic myeloproliferative disorder , define chronic eosinophilic leukemia ( CEL ) presence blast ( &gt; 10 % ) bone marrow ( BM ) , presence immature eosinophils different tissue , aggressive clinical course presence clonal cytogenetic anomaly . 4 . Myeloproliferative disorder ( MPD ) eosinophilia , eosinophilic leukemia chronic myelomonocytic leukemia [ myeloproliferative disorders/myelodysplastic syndrome ( MPD/MDS ) ] evidence : - ( 5 ; 12 ) ( q33 ; p13 ) cytogenetic fluorescent situ hybridization ( FISH ) analysis , - ETV6/TEL-PDGFRB fusion transcript reverse transcription polymerase chain reaction ( RT-PCR ) , - PDGFRB disruption , assess suspect , translocation additional partner gene ( H4 , HIP1 , CEV14 Rab5 ) 5 , - MPD/MDS constitutive activation gene platelet-derived growth factor receptor beta ( PDGFRB ) 6 point mutation</brief_summary>
	<brief_title>Study STI571 Treatment Patients With Idiopathic Hypereosinophilic Syndrome ( HES ) Eosinophilic Leukemias</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Presence primary secondary HES 2 . Not candidate allogeneic bone marrow transplantation . 3 . ECOG performance score 0 , 1 , 2 3 ( Karnofsky performance score &gt; 40 % ) . 4 . Life expectancy &gt; 4 week . 5 . Adequate hepatic renal function , define serum transaminase &lt; 2.5x upper limit normal ( ULN ) , bilirubin &lt; 1.5x ULN , creatinine &lt; 1.5x ULN . 6 . Age 18 year great . 7 . Postmenopausal , surgically sterile , take effective contraception female patient . 8 . Documentation write informed consent participate trial . 9 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . The presence follow exclude subject study enrollment : 1 . Patients clear evidence secondary hypereosinophilia . 2 . Acute myeloblastic leukemia inv ( 16 ) positive blast 3 . CBFbMYH11 transcript positive leukemia 4 . Lack recovery acute toxic effect previous chemotherapy [ common toxicity criterion ( CTC ) grade &gt; 1 ] exception chemotherapyinduced alopecia . 5 . Treatment investigational agent within 4 week prior study therapy . 6 . Major surgery within 4 week study start fully recover previous surgical procedure . 7 . Presence medical psychiatric condition may limit full compliance study increase risk associate study participation study drug administration , include limited 8 . Presence central nervous system ( CNS ) illness involvement disease . 9 . Active uncontrolled bacterial infection . 10 . Known human immunodeficiency virus ( HIV ) infection . 11 . Grade 3 4 bleeding . 12 . Significant cardiovascular disease ( i.e. , uncontrolled arrhythmia , unstable angina ) , major thromboembolic event ( myocardial infarction , stroke , transient ischemic attack , pulmonary embolism , noncatheterrelated deepvein thrombosis ) last 6 month . Due low cardiac toxicity profile Glivec , consider exclusion criterion presence severe complication viscera , among cardiopathy , particular endomyocardial fibrosis , due consider due HES . 13 . Increased blood eosinophil count due presence physiciandiagnosed asthma . However , due low pulmonary toxicity profile Glivec , consider exclusion criterion , HES associate asthma , presence severe complication damage lung , consider due HES . 14 . Pregnancy breastfeed . 15 . Malabsorption syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Hypereosinophilic Syndrome</keyword>
	<keyword>Eosinophilic leukemia</keyword>
	<keyword>STI571 ( Gleevec )</keyword>
	<keyword>PDGF receptor alpha</keyword>
	<keyword>Familiar hypereosinophilia</keyword>
	<keyword>Myeloproliferative disorder ( MPD ) eosinophilia</keyword>
	<keyword>myeloproliferative disorders/myelodysplastic syndrome</keyword>
</DOC>